Across 46 unique CTIS-authorized hepatocellular carcinoma / liver cancer Phase 2 & 3 trials in Europe, 18 trials had CRO or CRO-like operational vendor support, equal to 39.1%. ICON was the most active named provider, appearing in 7 of 18 CRO-supported trials, followed by Almac in 6, Parexel in 5, IQVIA in 5, and PPD in 4. CRO demand was strongest in multi-country, larger-site, pharma-sponsored, and advanced / unresectable / metastatic HCC studies.
Among 18 CRO-supported trials, ICON appeared in 7 trials (38.9%), Almac in 6 (33.3%), Parexel and IQVIA each in 5 (27.8%), and PPD in 4 (22.2%). Counts are trial-level: a provider is counted once per trial even if multiple related entities were listed.
The top CRO pattern is not a single full-service monopoly. ICON, Almac, Parexel, IQVIA and PPD recur across distinct operational layers: central lab, eCOA / IRT, monitoring, site management, supply, payments, and CTIS/EU execution support.
CRO use rises sharply once hepatocellular cancer trials move beyond a single-country setup. Only 2 of 21 single-country trials used CRO support (9.5%), compared with 16 of 25 multi-country trials (64.0%). Site scale also mattered: 11 of 18 trials with 16 or more sites used CRO support (61.1%).
| Capacity signal | CRO-supported | Share |
|---|---|---|
| 1 country | 2/21 | 9.5% |
| 2–5 countries | 11/17 | 64.7% |
| 6–10 countries | 5/8 | 62.5% |
| 16–30 sites | 7/10 | 70.0% |
| 31+ sites | 4/8 | 50.0% |
| 301+ participants | 2/3 | 66.7% |
The practical outsourcing threshold is not simply “large patient number.” CRO need appears most clearly when CTIS/EU coordination expands across countries and sites: CRO-supported trials averaged 4.8 countries and 20.6 sites, compared with 2.1 countries and 15.7 sites for non-CRO trials.
Advanced, unresectable or metastatic HCC had the strongest CRO signal: 8 of 13 trials used CRO support (61.5%). Basket or multi-tumor trials including HCC followed at 2 of 4 trials (50.0%), while broad / unspecified HCC trials used CRO support in 7 of 21 trials (33.3%).
CRO need concentrates where patient identification, cross-country site activation, radiology/lab workflows, and EU submission coordination are harder: advanced or unresectable HCC and basket studies that include HCC among several tumor types.
Third-party support was present in 31 of 46 trials (67.4%). The most frequent identifiable outsourced functions were central lab / bioanalysis / sample services in 13 of 46 trials (28.3%), digital data / eCOA / IRT in 13 (28.3%), and clinical operations / monitoring / site management in 10 (21.7%).
| Function | Trials | Share |
|---|---|---|
| Central lab / bioanalysis / sample services | 13/46 | 28.3% |
| Digital data / eCOA / IRT | 13/46 | 28.3% |
| Clinical operations / monitoring / site management | 10/46 | 21.7% |
| Supply / IMP logistics | 6/46 | 13.0% |
| Imaging / adjudication | 6/46 | 13.0% |
| Patient/site payments & reimbursement | 5/46 | 10.9% |
| Safety / pharmacovigilance | 5/46 | 10.9% |
The outsourcing market is functionally fragmented. In HCC Phase 2 & 3 trials, the strongest recurring demand is for central lab/sample infrastructure and digital trial systems, not only full-service clinical operations.
The 46 trials generated 145 country-level CTIS Part II / EU authorization tracks across 18 European countries. CRO-supported trials represented 18 of 46 trials (39.1%) but carried 86 of 145 country-level CTIS tracks (59.3%), showing that CRO need is disproportionately linked to multi-country EU submission execution.
CROs are most useful when sponsors must coordinate parallel CTIS/EU submissions, local Part II documents, site activation, patient allocation and country-specific authorization timelines across several European markets.
France had the broadest footprint with 30 trial participations, 267 listed sites and 1,468 participant allocations. Germany followed with 20 trial participations, 163 sites and 836 participants, while Spain had 22 trials, 128 sites and 617 participants.
| Country | Trials | Sites | Participants |
|---|---|---|---|
| France | 30 | 267 | 1,468 |
| Spain | 22 | 128 | 617 |
| Italy | 21 | 105 | 505 |
| Germany | 20 | 163 | 836 |
| Poland | 11 | 52 | 246 |
| Belgium | 9 | 23 | 112 |
France, Germany, Spain and Italy are the priority operational markets for HCC Phase 2 & 3 trial support. These countries combine high site density, repeated CTIS country participation and substantial patient allocation, making them natural targets for country-level submission and site-startup support.
Pharma / biotech sponsors used CRO support in 17 of 25 trials (68.0%), compared with 1 of 20 academic or hospital-sponsored trials (5.0%). Phase III trial records had CRO support in 8 of 19 unique trials (42.1%), while Phase II trial records had CRO support in 11 of 30 unique trials (36.7%).
Sponsor type is one of the clearest predictors of outsourcing. Pharma and biotech sponsors appear to externalize operational, lab, digital and EU submission support much more often than academic or hospital-led HCC studies.
HCC means hepatocellular carcinoma. CRO means contract research organization or operational vendor listed in CTIS sponsor third-party data as CRO-present support. CTIS means the Clinical Trials Information System used for EU clinical-trial submission and authorization workflows. Phase 2 & 3 refers to Phase II and Phase III cohort files; mixed Phase II/III trials are counted once at trial level in the overall denominator.